Header Image
Chronic pain and muscle tension in ADHD - neurophysiological correlates

Sitemap

Chronic pain and muscle tension in ADHD - neurophysiological correlates

For chronic pain and increased muscle tone as a symptom of ADHD, see Chronic pain / muscle tension in ADHD In the chapter Symptoms
For fibromyalgia as a comorbidity of ADHD see Fibromyalgia comorbid with ADHD in the article Diagnostics / Comorbidity in ADHD / Somatic comorbidities in ADHD

1. Chronic pain - development and causes

1.1. Chronic pain and dopamine

The dopamine system could be involved in ADHD, chronic pain and the modulation of muscle tone12 Chronic pain, depression and anxiety disorders show a high degree of comorbidity.3 Up to 80% of persons with ADHD or Parkinson’s disease report comorbid pain conditions, 2 to 3 times more often than non-affected people.34 In Parkinson’s, musculoskeletal pain is the most commonly reported pain condition at 40%-90%.54

The dopamine agonist apomorphine has an analgesic effect.6 Lesions of the dopaminergic terminals or the dopaminergic neurons in the midbrain (striatum, substantia nigra, VTA) cause pronounced pain reactions.7 Levodopa for Parkinson’s alleviates chronic pain.8
The dopaminergic mesolimbic reward circuit and the endocannabinoid system are involved in the pathology of chronic pain, both in pain perception and pain relief.3910
In anesthetized rats, painful pinching of the tail triggers dopamine release in the dorsal striatum and NAc nucleus during the stimulus, and dopamine release in the NAc shell after termination.11
Fibromyalgia, a chronic pain syndrome, is associated with a reduction in the release of dopamine1213 and reduced availability of D2/D3 receptors in the cortex14.
The mesolimbic reward circuit is involved in the perception of pain and the expectation of pain relief.15

Painful stimuli are encoded by the mesolimbic dopamine circuit. Chronic pain reduces tonic dopamine. A pain-induced reduction in tonic dopamine correlates with increased evoked phasic dopamine release.16 This is consistent with Grace’s model of decreased tonic and increased phasic dopamine firing in ADHD. See also Tonic and phasic dopamine in explanatory models of ADHD In the section Dopamine in the chapter Neurological aspects.
People with chronic pain show reduced responsiveness within the mesolimbic dopamine system to meaningful stimuli, reduced D2 receptor binding, reduced presynaptic dopamine activity in the striatum at rest and after an acute pain stimulus.17 In animals, chronic pain leads to decreased c-Fos activation in the VTA, decreased total dopamine levels and decreased D2 receptors in the striatum.17
Conversely, a reduction of dopamine in the brain by acute depletion of the dopamine precursors phenylalanine and tyrosine caused increased subjective pain sensitivity (the degree to which pain was perceived as unpleasant) without altering the sensory perception of pain.18
In 6-OHDA mice, in which dopamine synthesis is chemically damaged and which thus represent an ADHD animal model, an increased sensitivity to pain was found. The pain sensitivity was presumably mediated by α- and β-adrenergic and D2/D3 receptors. Atomoxetine19 such as MPH20 was able to reduce the increased pain sensitivity in ADHD.
Stimulation of the substantia nigra, one of the two most important sources of dopamine in the brain, causes pain relief by activating spinal cord neurons via dopaminergic signaling pathways.212223 Painful stimuli cause a release of dopamine in the dorsolateral striatum, which correlates with the subjective perception of pain intensity. The ventral striatum is also clearly associated with the emotional dimension of the human pain process and the expectation of pain.24

In Parkinson’s disease, which is also characterized by dopamine deficiency, 30 to 50 % of people with ADHD suffer from increased sensitivity to pain.25 This can be improved by dopaminergic medication26, e.g. levodopa or deep brain stimulation.27

Conversely, the perception of pain is reduced in schizophrenia, which is associated with increased dopamine levels.2829

The endocannabinoid system modulates the dopaminergic system in a variety of ways, including in relation to reward processing, and is also crucially involved in the perception of pain.3
More on the interaction between Endocannabinoids and dopamine In the article Cannabinoids in the section Neurotransmitters in the chapter Neurological aspects.

1.2. Other pathways for chronic pain in ADHD

Other common mechanisms for ADHD and chronic pain are discussed:1

  • Genetic factors30
  • Traumas3031
  • Pain receptors (opioid receptors, cannabinoid receptors, alpha-2-adrenoceptors)30
  • GABAergic neurosteroids (allopregnanolone, pregnanolone), progesterone30
  • Dysfunction of the HPA axis30
  • Neuroinflammation3032
  • BDNF30
  • changed sensitivity to pain32
  • long-lasting muscle contraction, high muscle tone33
    • almost 90% of children and adults with ADHD show motor dysregulation, which leads to persistently high muscle tone
    • this could contribute to the development of chronic muscle pain in ADHD34
    • A highly significant correlation was found between muscular regulation problems and pain intensity34
      • the ADHD group showed increased tone in the muscles of the neck, back, chest, shoulders, hips (i.e. the axial and proximal stabilizing muscles) and legs34 Increased tone in these muscles was also found in children with ADHD.

1.3. Pathways of development of fibromyalgia

For fibromyalgia, an interplay of several pathogenic mechanisms has been proposed as a neurophysiological pathway:3531

  • Increase in the activity of the excitatory pain pathways bottom up
    • Increase in transmitters such as
      • Substance-P
      • Nitrogen oxide
      • Nerve growth factor (NGF)
      • Glutamate.
  • Reduced activity of the inhibitory top-down pathways
    • reduced levels of
      • Dopamine
      • Noradrenaline
      • Serotonin
      • endogenous opioids
  • Consequences of the imbalance of overactivated pain pathways and underactivated prefrontal inhibition:
    • functional central sensitization
    • which is developing into structural central sensitization
      • widespread reduction of the pain threshold
      • Increase in summation over time
      • prolonged after-effects of harmful stimuli
      • reduced general pain tolerance
  • In addition, chronic sympathetic hyperactivity with increased sensitivity to acute stress exacerbates the symptoms of pain and fatigue
  • HPA axis disturbed in the sense of chronic hypoactivity
    • Flattening of the daily cortisol fluctuations
      also promotes pain symptoms, fatigue and depression
  • Peripheral pathogenic processes
    • Impairment of nociceptor sensitivity
    • immunological changes
    • local metabolic mechanisms in the muscles
      • ATP depletion
      • Lactic acid enrichment
      • Hypocarbia

Dopamine is also involved in fibromyalgia.2
Pain perception and attention influence each other.36
In somatoform disorders such as fibromyalgia, irritable bowel syndrome, functional dyspeptic syndrome and temporomandibular joint dysfunction, melatonin is said to be a possible treatment option for pain symptoms.37

2. Muscle tone - causes of development

2.1. Muscle tone and dopamine

Dopamine influences the tone of skeletal muscles and can therefore directly control movement:38
The dopamine agonist apomorphine activated motoneurons of the trigeminal nerve and strongly increased the tone of the masseter (a chewing muscle) and tensor palatini (a muscle of the soft palate that supports swallowing). This excitatory effect is mediated by D1-like receptors, as specific activation of D1-like receptors increased muscle tone and blockade of these receptors prevented dopamine-induced activation of motor neurons. Blockade of D1-like receptors alone had no detectable effect on masseter/tensor palatini basal tone, suggesting that there is no functional dopamine drive on trigeminal motoneurons, at least during isoflurane anesthesia. In contrast, D2-like receptors did not affect the function of trigeminal motoneurons or the tone of masseter or tensor palatini.

In muscle tension tests, 64 to 84% of persons with ADHD showed severe impairment, compared to 0% of non-affected people.39

Prolonged muscle tension can cause chronic pain.33

An adult person with ADHD reported to us a massive decrease in his decades of massive neck/shoulder tension when he drastically reduced his chronic alcohol consumption.

2.2. Other pathways for high muscle tension in ADHD

  • The reticular system
    • is involved in34
      • Regulation of the arousals
      • Maintaining muscle tone.
    • The reticular formation can 34
      • activate several muscles at the same time
      • Modulate body position adjustments for balance
      • this can affect the stabilizing muscles (the proximal limb muscles and muscles that stabilize the spine).
    • The reticulospinal system (the entirety of the descending fibers from the reticular formation) is important for34
      • Regulation of posture control
      • Regulation of movements
      • Reduction in muscle activity during REM sleep

  1. Udal ABH, Stray LL, Stray T, Bertelsen TB, Pripp AH, Egeland J (2024): ADHD-pain: Characteristics of chronic pain and association with muscular dysregulation in adults with ADHD. Scand J Pain. 2024 Sep 9;24(1). doi: 10.1515/sjpain-2024-0015. PMID: 39253953.

  2. Wood PB, Holman AJ (2009): An elephant among us: the role of dopamine in the pathophysiology of fibromyalgia. J Rheumatol. 2009 Feb;36(2):221-4. doi: 10.3899/jrheum.080583. PMID: 19208556.

  3. Mlost J, Wąsik A, Starowicz K (2019): Role of endocannabinoid system in dopamine signalling within the reward circuits affected by chronic pain. Pharmacol Res. 2019 May;143:40-47. doi: 10.1016/j.phrs.2019.02.029. PMID: 30831242. REVIEW

  4. Young Blood MR, Ferro MM, Munhoz RP, Teive HA, Camargo CH (2016): Classification and Characteristics of Pain Associated with Parkinson’s Disease. Parkinsons Dis. 2016;2016:6067132. doi: 10.1155/2016/6067132. PMID: 27800210; PMCID: PMC5069361. REVIEW

  5. Skogar O, Lokk J (2016): Pain management in patients with Parkinson’s disease: challenges and solutions. J Multidiscip Healthc. 2016 Sep 30;9:469-479. doi: 10.2147/JMDH.S105857. PMID: 27757037; PMCID: PMC5053370. REVIEW

  6. Dennis SG, Melzack R (1983): Effects of cholinergic and dopaminergic agents on pain and morphine analgesia measured by three pain tests. Exp Neurol. 1983 Jul;81(1):167-76. doi: 10.1016/0014-4886(83)90166-8. PMID: 6861945.

  7. Saadé NE, Atweh SF, Bahuth NB, Jabbur SJ (1997): Augmentation of nociceptive reflexes and chronic deafferentation pain by chemical lesions of either dopaminergic terminals or midbrain dopaminergic neurons. Brain Res. 1997 Mar 14;751(1):1-12. doi: 10.1016/s0006-8993(96)01164-x. PMID: 9098562.

  8. Nebe A, Ebersbach G (2009): Pain intensity on and off levodopa in patients with Parkinson’s disease. Mov Disord. 2009 Jun 15;24(8):1233-7. doi: 10.1002/mds.22546. PMID: 19412949.

  9. Farmer MA, Baliki MN, Apkarian AV (2012): A dynamic network perspective of chronic pain. Neurosci Lett. 2012 Jun 29;520(2):197-203. doi: 10.1016/j.neulet.2012.05.001. PMID: 22579823; PMCID: PMC3377811. REVIEW

  10. Navratilova E, Porreca F (2014): Reward and motivation in pain and pain relief. Nat Neurosci. 2014 Oct;17(10):1304-12. doi: 10.1038/nn.3811. PMID: 25254980; PMCID: PMC4301417. REVIEW

  11. Budygin EA, Park J, Bass CE, Grinevich VP, Bonin KD, Wightman RM (2012): Aversive stimulus differentially triggers subsecond dopamine release in reward regions. Neuroscience. 2012 Jan 10;201:331-7. doi: 10.1016/j.neuroscience.2011.10.056. PMID: 22108611; PMCID: PMC3258373.

  12. Wood PB, Patterson JC 2nd, Sunderland JJ, Tainter KH, Glabus MF, Lilien DL (2007): Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain. 2007 Jan;8(1):51-8. doi: 10.1016/j.jpain.2006.05.014. PMID: 17023218.

  13. Wood PB, Schweinhardt P, Jaeger E, Dagher A, Hakyemez H, Rabiner EA, Bushnell MC, Chizh BA (2007): Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci. 2007 Jun;25(12):3576-82. doi: 10.1111/j.1460-9568.2007.05623.x. PMID: 17610577.

  14. Albrecht DS, MacKie PJ, Kareken DA, Hutchins GD, Chumin EJ, Christian BT, Yoder KK (2016): Differential dopamine function in fibromyalgia. Brain Imaging Behav. 2016 Sep;10(3):829-39. doi: 10.1007/s11682-015-9459-4. PMID: 26497890; PMCID: PMC4842344.

  15. Seymour B, O’Doherty JP, Koltzenburg M, Wiech K, Frackowiak R, Friston K, Dolan R (2005): Opponent appetitive-aversive neural processes underlie predictive learning of pain relief. Nat Neurosci. 2005 Sep;8(9):1234-40. doi: 10.1038/nn1527. PMID: 16116445.

  16. Gee TA, Weintraub NC, Lu D, Phelps CE, Navratilova E, Heien ML, Porreca F (2020): A pain-induced tonic hypodopaminergic state augments phasic dopamine release in the nucleus accumbens. Pain. 2020 Oct;161(10):2376-2384. doi: 10.1097/j.pain.0000000000001925. PMID: 32453137; PMCID: PMC7508893.

  17. Taylor AMW, Becker S, Schweinhardt P, Cahill C (2016): Mesolimbic dopamine signaling in acute and chronic pain: implications for motivation, analgesia, and addiction. Pain. 2016 Jun;157(6):1194-1198. doi: 10.1097/j.pain.0000000000000494. PMID: 26797678; PMCID: PMC4866581.

  18. Tiemann L, Heitmann H, Schulz E, Baumkötter J, Ploner M (2014): Dopamine precursor depletion influences pain affect rather than pain sensation. PLoS One. 2014 Apr 23;9(4):e96167. doi: 10.1371/journal.pone.0096167. PMID: 24760082; PMCID: PMC3997524.

  19. Sifeddine W, Ba-M’hamed S, Landry M, Bennis M (2023): Effect of atomoxetine on ADHD-pain hypersensitization comorbidity in 6-OHDA lesioned mice. Pharmacol Rep. 2023 Feb 14. doi: 10.1007/s43440-023-00459-3. PMID: 36787018.

  20. Treister R, Eisenberg E, Demeter N, Pud D (2015): Alterations in pain response are partially reversed by methylphenidate (Ritalin) in adults with attention deficit hyperactivity disorder (ADHD). Pain Pract. 2015 Jan;15(1):4-11. doi: 10.1111/papr.12129. PMID: 24134430.

  21. Burkey AR, Carstens E, Jasmin L (1999): Dopamine reuptake inhibition in the rostral agranular insular cortex produces antinociception. J Neurosci. 1999 May 15;19(10):4169-79. doi: 10.1523/JNEUROSCI.19-10-04169.1999. PMID: 10234044; PMCID: PMC6782709.

  22. Li J, Ji YP, Qiao JT, Dafny N (1992): Suppression of nociceptive responses in parafascicular neurons by stimulation of substantia nigra: an analysis of related inhibitory pathways. Brain Res. 1992 Sep 18;591(1):109-15. doi: 10.1016/0006-8993(92)90984-h. PMID: 1446222.

  23. Baumeister AA, Anticich TG, Hawkins MF, Liter JC, Thibodeaux HF, Guillory EC (1988): Evidence that the substantia nigra is a component of the endogenous pain suppression system in the rat. Brain Res. 1988 Apr 26;447(1):116-21. doi: 10.1016/0006-8993(88)90971-7. PMID: 3382946.

  24. Juri C, Rodriguez-Oroz M, Obeso JA (2010): The pathophysiological basis of sensory disturbances in Parkinson’s disease. J Neurol Sci. 2010 Feb 15;289(1-2):60-5. doi: 10.1016/j.jns.2009.08.018. PMID: 19758602.

  25. Fil A, Cano-de-la-Cuerda R, Muñoz-Hellín E, Vela L, Ramiro-González M, Fernández-de-Las-Peñas C (2013): Pain in Parkinson disease: a review of the literature. Parkinsonism Relat Disord. 2013 Mar;19(3):285-94; discussion 285. doi: 10.1016/j.parkreldis.2012.11.009. PMID: 23246139.

  26. Thompson T, Gallop K, Correll CU, Carvalho AF, Veronese N, Wright E, Stubbs B (2017): Pain perception in Parkinson’s disease: A systematic review and meta-analysis of experimental studies. Ageing Res Rev. 2017 May;35:74-86. doi: 10.1016/j.arr.2017.01.005. PMID: 28179128.

  27. Cury RG, Galhardoni R, Fonoff ET, Perez Lloret S, Dos Santos Ghilardi MG, Barbosa ER, Teixeira MJ, Ciampi de Andrade D (2016): Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms. Eur J Pain. 2016 Feb;20(2):151-65. doi: 10.1002/ejp.745. PMID: 26147660.

  28. Stubbs B, Thompson T, Acaster S, Vancampfort D, Gaughran F, Correll CU (2015): Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies. Pain. 2015 Nov;156(11):2121-2131. doi: 10.1097/j.pain.0000000000000304. PMID: 26207650. METASTUDIE

  29. Jarcho JM, Mayer EA, Jiang ZK, Feier NA, London ED (2012): Pain, affective symptoms, and cognitive deficits in patients with cerebral dopamine dysfunction. Pain. 2012 Apr;153(4):744-754. doi: 10.1016/j.pain.2012.01.002. PMID: 22386471; PMCID: PMC3816524. REVIEW

  30. Johnston KJA, Huckins LM (2022): Chronic Pain and Psychiatric Conditions. Complex Psychiatry. 2022 Sep 15;9(1-4):24-43. doi: 10.1159/000527041. PMID: 37034825; PMCID: PMC10080192. REVIEW

  31. Bou Khalil R, Khoury E, Richa S (2018): The Comorbidity of Fibromyalgia Syndrome and Attention Deficit and Hyperactivity Disorder from a Pathogenic Perspective. Pain Med. 2018 Sep 1;19(9):1705-1709. doi: 10.1093/pm/pny142. PMID: 30053155.

  32. Kerekes N, Sanchéz-Pérez AM, Landry M (2021): Neuroinflammation as a possible link between attention-deficit/hyperactivity disorder (ADHD) and pain. Med Hypotheses. 2021 Dec;157:110717. doi: 10.1016/j.mehy.2021.110717. PMID: 34717072.

  33. Mense S, Masi AT (2010): Increased muscle tone as a cause of muscle pain. In: Mense S, Gerwin RD, editors. Muscle pain: understanding the mechanisms. Berlin, Heidelberg: Springer; 2010. p. 207–49.10.1007/978-3-540-85021-2_6

  34. Stray, Kristensen, Lomeland, Skorstad, Stray, Tønnessen (2013): Motor regulation problems and pain in adults diagnosed with ADHD. Behav Brain Funct. 2013 May 3;9:18. doi: 10.1186/1744-9081-9-18. PMID: 23642255; PMCID: PMC3652792.

  35. Bou Khalil R, Khoury E, Richa S (2016): Do Fibromyalgia Flares Have a Neurobiological Substrate? Pain Med. 2016 Mar;17(3):469-475. doi: 10.1093/pm/pnw008. PMID: 26917625.

  36. Van Ryckeghem DML, Rost S, Kissi A, Vögele C, Crombez G (2018): Task interference and distraction efficacy in patients with fibromyalgia: an experimental investigation. Pain. 2018 Jun;159(6):1119-1126. doi: 10.1097/j.pain.0000000000001196. PMID: 29521810.

  37. Geoffroy, Micoulaud Franchi, Lopez, Schroder (2019): membres du consensus Mélatonine SFRMS. The use of melatonin in adult psychiatric disorders: Expert recommendations by the French institute of medical research on sleep (SFRMS). Encephale. 2019 Nov;45(5):413-423. doi: 10.1016/j.encep.2019.04.068. PMID: 31248601.

  38. Schwarz PB, Peever JH (2011): Dopamine triggers skeletal muscle tone by activating D1-like receptors on somatic motoneurons. J Neurophysiol. 2011 Sep;106(3):1299-309. doi: 10.1152/jn.00230.2011. PMID: 21653722.

  39. Stray LL, Stray T, Iversen S, Ruud A, Ellertsen B, Tønnessen FE (2009): The Motor Function Neurological Assessment (MFNU) as an indicator of motor function problems in boys with ADHD. Behav Brain Funct. 2009 May 18;5:22. doi: 10.1186/1744-9081-5-22. PMID: 19450246; PMCID: PMC2697164. 13 - 16 in Table 3)

Diese Seite wurde am 24.05.2025 zuletzt aktualisiert.